Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts
© Braidy et al.; licensee BioMed Central Ltd. 2013
Received: 3 June 2013
Accepted: 1 October 2013
Published: 4 October 2013
The accumulation and aggregation of alpha-synuclein (α-syn) in several tissue including the brain is a major pathological hallmark in Parkinson’s disease (PD). In this study, we show that α-syn can be taken up by primary human cortical neurons, astrocytes and skin-derived fibroblasts in vitro. Our findings that brain and peripheral cells exposed to α-syn can lead to impaired mitochondrial function, leading to cellular degeneration and cell death, provides additional evidence for the involvement of mitochondrial dysfunction as a mechanism of toxicity of α-syn in human cells.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease (AD) . This debilitating degenerative movement disorder is characterized symptomatically by resting tremor, bradykinesia, muscle tone rigidity and impaired autonomic, sensory and cognitive function. These motor deficits are attributed to the selective loss of dopaminergic neurons projecting from the substantia nigra to the midbrain. Dystrophic neurons typically contain cytosolic protein aggregates (“Lewy bodies”) composed largely of the presynaptic protein alpha-synuclein . While numerous neurotoxins and genes have been implicated in the development of PD, the exact aetiology of PD remains unclear [1–5]. Accumulative evidence suggests that α-syn may be involved in the initiation and disease progression [6, 7]. Familial forms of PD are associated with either missense of gene mutations in the SNCA gene encoding for α-syn . Mutations in the α-syn gene locus represents an important risk factor for PD in several genome-wide association studies using large cohorts worldwide .
The α-syn is a cytosolic protein that can be released from neuronal cells in small amounts via unconventional exocytosis under normal physiological conditions [10, 11]. However, in the presence of several stressors, α-syn may be released from neuronal cells into the surrounding extracellular space in larger quantities and taken up by neighbouring cells by endocytosis [10, 11]. However, little is known regarding the effect of human recombinant α-syn on other cells of the brain and surrounding tissue.
In this study, we have shown that human recombinant α-syn can be taken up by human primary astrocytes, cortical neurons and fibroblasts. We also show that this may lead to increased intracellular oxygen consumption and cell death after 24 hour exposure. The effect of α-syn in vitro, even in cultured fibroblasts, suggests that PD may be a systemic illness, with primary pathological changes occurring in the brain.
Materials and methods
Reagents and chemicals
Dulbecco’s phosphate buffer solution (DPBS) and all other cell culture media and supplements were from Invitrogen (Melbourne, Australia) unless otherwise stated. Mouse mAb anti-α-syn, DAPI, and pAb anti-GFAP were obtained from Sigma-Aldrich (Castle-Hill, Australia). Rabbit anti-MAP2 and anti-fibronectin were obtained from Millipore (Melbourne, Australia). Secondary anti-mouse IgG and anti-rabbit Alexa 488 (green) or Alexa 594 (red)-conjugated antibodies were purchased from Molecular Probes (Eugene, OR). All commercial antibodies were used at the concentrations specified by the manufacturers.
Human foetal brains, and skin were obtained from 16–19 week old foetuses collected following therapeutic termination with informed consent. Mixed brain cultures were prepared and maintained using a protocol previously described .
Astrocytes were prepared from the mixed brain cell cultures using a protocol previously described . Cells were cultured in medium RPMI 1640 (Invitrogen) supplemented with 10% foetal bovine serum, 1% 1-glutamax, 1% antibacterial/antifungal, and 0.5% glucose. Cells were seeded into 24-well tissue culture plates to a density of 1 × 105 cells 24 hours prior to experimentation.
Human foetal cortical neurons were prepared from mixed brain cell cultures as previously described . Briefly, cortical neurons were plated in 24-well culture plates coated with Matrigel (BD Biosciences) diluted 1/20 in Neurobasal (Invitrogen). The culture medium was changed every second day and consisted of Neurobasal medium supplemented with 1% B-27 supplement, 1% Glutamax, 1% antibiotic/antifungal, and 0.5% glucose.
Fibroblasts were prepared from the skin using a protocol as previously described . All cell cultures were maintained in an incubator at 37°C in a humidified atmosphere containing 95% air/5% CO2.
Uptake of recombinant extracellular α-synuclein
Recombinant α-synuclein was expressed in Escherichia coli BL21(DE3) transformed with the pET11d vector containing the human α-synuclein cDNA described previously . For uptake of recombinant α-syn in primary astrocytes, cortical neurons and skin-derived fibroblasts, human α-syn was incubated overnight at 37°C to form oligomers and then labelled with Alexa Fluor 488 (Invitrogen) as per the manufacturer’s instructions. Cells were incubated with expansion media containing 1 μM Alexa-Fluor-488-labelled α-syn for 30 min and 60 min. Cells were washed twice with PBS to ensure that the uptake of exogenous α-syn was not due to non-specific binding of α-syn to the cells.Cells were fixed with 4% paraformaldehyde diluted in DPBS.
Immunocytochemistry for the detection of α-syn uptake
The method for immunocytochemistry has been previously described . Cells were incubated with selected primary antibody mAb α-syn, together with phenotypic markers (GFAP, MAP-2, Fibronectin) and antibody against the inner mitochondrial membrane protein, complex V (ATPase) (Abcam). Selected secondary antibodies (goat anti-mouse IgG or goat anti-rabbit coupled with Alexa 488 or Alexa 594) were used. The following controls were performed for each labelled experiment: (1) isotypic antibody controls; and (2) incubation with only the secondary labelled antibody.
Extracellular LDH activity as a measurement for cytotoxicity
The release of lactate dehydrogenase (LDH) into culture supernatant correlates with the amount of cell death and membrane damage, providing an accurate measure of cellular toxicity. LDH activity was assayed on cortical neurons, astrocytes and skin-derived fibroblasts treated with 5 μM recombinant α-syn after 24 hours incubation using a standard spectrophotometric technique described by .
XF24 Microplate-based respirometry
To determine the effect of exogenous recombinant α-syn (5 μM) on oxygen consumption rates (OCRs; as indicator of mitochondrial respiration) in cortical neurons, primary astrocytes, and skin-derived fibroblasts, the Seahorse XF24, extracellular flux analyzer (Seahorse Bioscience, North Billerica, MA, USA) was employed as previously described. Briefly, culture plates were incubated in a CO2-free incubator at 37°C for 1 hr to equilibrate for temperature and pH. The microplate was then loaded into the XF24 and further incubated for 15 min by 3 min mix, 2 min wait cycles before commencement of the assay. The XF assay was performed as previous described . After determination of the basal respiration in the cell culture, oligomycin (2 μM), carbonylcyanide-p-trifluoromethoxy-phenylhydrazone (FCCP, 500 nM), and antimycin (3 μM) were sequentially added and the oxygen consumption rates (OCRs) for each culture well were quantified for 2 minutes. This allowed us to determine the basal control ratio (BCR) and the uncoupling ratio (UCR) . Essentially, the BCR is a measurement of how close the basal level of respiration is to the maximum level of respiration (i.e., basal/maximum). The closer this ratio is to 1, the lower the maximum level of respiration, and thus represents an indication of mitochondrial malfunction. The UCR is a measurement of mitochondrial functional integrity and measures the ratio of uncoupled to physiologically normal respiration levels (i.e., maximum/basal). The greater the maximum level of respiration, the greater the mitochondrial functional integrity.
Bradford protein assay for the quantification of total protein
Extracellular LDH activity, NAD+ concentration, nuclei and mitochondrial protein content, and mitochondrial function were corrected for variations in protein concentration using the Bradford protein assay described by Bradford .
Results obtained are presented as the means ± the standard error of measurement (SEM). One way analysis of variance (ANOVA) and post hoc Tukey’s multiple comparison tests were used to determine statistical significance between treatment groups. Differences between treatment groups were considered significant if p was less than 0.05 (p < 0.05). Experiments were performed in triplicates using cells derived from three different specimens unless otherwise stated.
Time dependent uptake of α-syn in cultured human cortical neurons, astrocytes and skin-derived fibroblasts
Cytotoxic effects of α-syn in enteric neurons is associated increased intracellular oxygen consumption leading to cell death
The current study uses several cell culture models: 1) to reaffirm whether recombinant α-syn can be taken up by primary human astrocytes, cortical neurons and fibroblasts; 2) to determine the effect of α-syn on mitochondrial function in brain and periphery cells using Seahorse XF240. A key finding of the current investigation is that α-syn can accumulate in several cell types in vitro not restricted to the brain, in a time dependent manner leading to increased intracellular oxygen consumption and cell death.
Owing to the diverse clinical symptoms associated with PD, it is likely that multiple brain systems may be impaired. Indeed, Lewy bodies are widely distributed in the several areas of the brain, including the midbrain, cerebrum and brainstem corresponding to axonal projections . Earlier studies have suggested that misfolded α-syn may propagate from neuron to neuron in a prion-like manner, causing endogenous α-syn to misfold . Recently, Freundt et al.  showed that fibrillar α-synuclein can be internalized by primary mouse neurons via rapid axonal transport with saltatory movement . Moreover, Angot et al.  showed that α-syn can be transferred between neuronal host cells and grafted dopaminergic neurons in vivo. However, our data is the first to demonstrate the uptake of exogenous α-syn oligomers in human primary cortical neurons. Taken together, these results support the hypothesis that PD can be caused by neuron-to-neuron spread of α-syn aggregates involving axonal transport of fibrillar and/or oligomers.
Glial inclusions, which are common pathological features in PD, have been shown to occur as a result of neuron-to-glia transmission of α-syn protein . Here, we show that human primary astrocytes can also uptake α-syn oligomers similar to murine glial cells. One study showed that glial accumulation of α-syn proteins released from murine neuronal cells may involve endocytosis leading to the formation of cytoplasmic inclusion bodies . Furthermore, astrocytes exposed to neuronal α-syn exhibited significant changes in their gene expression profile providing biochemical evidence for an inflammatory response. Up-regulation of pro-inflammatory cytokines and chemokines correlated positively with the degree of accumulation of α-syn in glial cells . Together, these results suggest that astroglial alpha-synuclein pathology is produced by direct transmission of neuronal alpha-synuclein aggregates, causing inflammatory responses. This transmission step is thus an important mediator of pathogenic glial responses and could qualify as a new therapeutic target.
Our data is also in line with previous studies showing increased α-syn expression in Parkinson patient fibroblasts parallel to increased oxidative stress in these cells . Without an appropriate mechanism of uptake into these distinct cell types, these observed patterns cannot be fully evaluated. They do, however, suggest that α-syn toxicity may not be restricted to the central and peripheral nervous system but may also be associated with other systems such as the skin. For example, it might be reasonable to hypothesise that α-syn aggregates can progress from neurons, and dissociate to interact with other cells, and vice versa, hence leading to a reduction in function which is not restricted to neuronal cells.
Mitochondrial dysfunction has been frequently documented in the neurodegenerative process that underlies PD [10, 28–35]. Despite this, the molecular events leading to the observed dysfunction remains unclear. The goal of this study was also to investigate the effects of recombinant α-syn cell viability and mitochondrial function in primary human neurons, astrocytes and fibroblasts. Our data shows a significant increase in lactate dehydrogenase (LDH) release and indicating a reduction in cell viability in α-syn treated cells compared to non-treated controls. With regards to mitochondrial function, α-syn exhibited a significant reduction in oxygen consumption in these cells, as observed by an increase in the BCR ratio and a decline in the UCR. Importantly, these data also support a previous PD respiratory analysis study which found that α-syn over-expression also reduced the mitochondrial maximum respiration rate and increased mitochondrial fragmentation .
While α-syn is a well known cytoplasmic protein, numerous studies have shown that it has some affinity to phospholipids, and vesicles [36, 37]. Herein we have shown that α-syn is also delivered to the mitochondria. Another study has shown that α-syn is present in nanomolar concentrations in neuronal culture medium . Secreted forms of α-syn have been shown to re-enter adjacent cells leading to increased cytotoxicity via oxidative stress mechanisms [22, 25]. In the present study, we showed that, in cultured neurons, glial cells and skin-derived fibroblasts, α-syn could form intracellular inclusions. Our study does not rule out the possibility that the internalized recombinant α-syn may be entangled with endogenous α-syn, and that the α-syn expression visualised herein may consist of both naturally occurring endogenous and recombinant exogenous α-syn. However, using our method, it is clear that endogenous α-syn is only expressed at very low levels in foetal tissue, and not detected using immunohistochemistry. Further work is warranted to investigate the binding properties of α-syn in cultured human cells.
The current data is consistent with mitochondrial dysfunction as the converging pathway connecting a variety of causes for PD. In fact, several causes of mitochondrial dysfunction due to free radicals and lysosomal/proteasome dysfunction associated with α-syn have been reported in PD [28, 39, 40]. One study showed a higher frequency in somatic mitochondrial DNA deletion in the substantia nigra of sporadic PD patients leading to deficiency in the respiratory chain and increased generation of reactive oxygen species . These results are in line with our current work indicating that PD may occur in response to mitochondrial dysfunction, possibly due to alterations in gene expression.
This work was supported by the UNSW Faculty of Medicine Research Grant to Dr Nady Braidy. Dr Nady Braidy is also the recipient of an Alzheimer’s Australia Viertel Foundation and the National Health and Medical Research Council Early Career Research Fellowship at the University of New South Wales. This work has been also supported by the Alzheimer’s Association (grant#IIRG- 08–89545) and by the Rebecca Cooper foundation (Australia).
- Fahn S, Sulzer D: Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1(1):139-154. 10.1602/neurorx.1.1.139PubMed CentralView ArticlePubMedGoogle Scholar
- Keeney P, Xie J, Capaldi R, Benenett J: Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci Res 2006, 26: 5256-5264. 10.1523/JNEUROSCI.0984-06.2006View ArticleGoogle Scholar
- Goetze O, Woitalla D: The role of MPTP in Parkinson’s disease: connecting brain and gut? Exp Neurol 2008, 210(2):281-285. 10.1016/j.expneurol.2008.01.004View ArticlePubMedGoogle Scholar
- Halliday G, McCann H: Human-based studies on alpha-synuclein deposition and relationship to Parkinson’s disease symptoms. Exp Neurol 2008, 2008: 12-21.View ArticleGoogle Scholar
- Lesage S, Brice A: Parkinson’s Disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009, 18: R48-R59. 10.1093/hmg/ddp012View ArticlePubMedGoogle Scholar
- Spillantini M, Schmidt M, Lee V, Trojanowski J, Jakes R, Goerdert M: Alpha-synuclein in lewy bodies. Nature 1997, 388: 839-840. 10.1038/42166View ArticlePubMedGoogle Scholar
- Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M: Alpha-synuclein in filamentous inclusions of lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998, 95(11):6469-6473. 10.1073/pnas.95.11.6469PubMed CentralView ArticlePubMedGoogle Scholar
- Wider C, Ross OA, Nishioka K, Heckman MG, Vilarino-Guell C, Jasinska-Myga B, Erketin-Taner N, Rademakers R, Graff-Radford NR, Mash DC, Papapetropoulos S, Duara R, Uchikado H, Wszolek ZK, Farrer MJ, Dickson DW: An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer’s and lewy body pathology. J Neurol Neurosurg Psychiatry 2012, 83(4):424-429. 10.1136/jnnp-2011-301413PubMed CentralView ArticlePubMedGoogle Scholar
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276(5321):2045-2047. 10.1126/science.276.5321.2045View ArticlePubMedGoogle Scholar
- Lee HJ, Patel S, Lee SJ: Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005, 25(25):6016-6024. 10.1523/JNEUROSCI.0692-05.2005View ArticlePubMedGoogle Scholar
- Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ: Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem 2010, 113(5):1263-1274.PubMedGoogle Scholar
- Guillemin GJ, Smythe G, Takikawa O, Brew BJ: Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49(1):15-23. 10.1002/glia.20090View ArticlePubMedGoogle Scholar
- Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ: Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001, 78: 1-13. 10.1046/j.1471-4159.2001.00397.xView ArticleGoogle Scholar
- Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ: Characterization of the kynurenine pathway in human neurons. J Neurosci 2007, 27(47):12884-12892. 10.1523/JNEUROSCI.4101-07.2007View ArticlePubMedGoogle Scholar
- Asp L, Johansson A-S, Mann A, Owe-Larsson B, Urbanska E, Kocki T, Kesel M, Engberg G, Lundkvist G, Karlsson H: Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts. J Inflamm 2011, 8: 25. 10.1186/1476-9255-8-25View ArticleGoogle Scholar
- Jensen PH, Islam K, Kenney J, Nielsen MS, Power J, Gai WP: Microtubule-associated protein 1B is a component of cortical lewy bodies and binds alpha-synuclein filaments. J Biol Chem 2000, 275(28):21500-21507. 10.1074/jbc.M000099200View ArticlePubMedGoogle Scholar
- Guillemin G, Smythe G, Takikawa O, Brew BJ: Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes and neurons. Glia 2004, 49: 15-23.View ArticleGoogle Scholar
- Koh JY, Choi DW: Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 1987, 20: 83-90. 10.1016/0165-0270(87)90041-0View ArticlePubMedGoogle Scholar
- Schuh R, Clerc P, Hwang H-J, Mehrabiab Z, Bittman K, Chen H, Polster B: Adaptation of microplate-based respirometry for hippocampal slices and analysis of respiratory capacity. J Neurosci Res 2011, 89: 1979-1988. 10.1002/jnr.22650PubMed CentralView ArticlePubMedGoogle Scholar
- Pesta D, Gnaiger E: High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol 2012, 810: 25-58. 10.1007/978-1-61779-382-0_3View ArticlePubMedGoogle Scholar
- Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 1976, 53: 452-458.Google Scholar
- Konno M, Hasegawa T, Baba T, Miura E, Sugeno N, Kikuchi A, Fiesel FC, Sasaki T, Aoki M, Itoyama Y, Takeda A: Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol Neurodegener 2012, 7: 38. 10.1186/1750-1326-7-38PubMed CentralView ArticlePubMedGoogle Scholar
- Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24(2):197-211. 10.1016/S0197-4580(02)00065-9View ArticlePubMedGoogle Scholar
- Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M, Melki R, Kirkegaard K, Brahic M: Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol 2012, 72(4):517-524. 10.1002/ana.23747PubMed CentralView ArticlePubMedGoogle Scholar
- Angot E, Steiner JA, Lema Tome CM, Ekstrom P, Mattsson B, Bjorklund A, Brundin P: Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 2012, 7(6):e39465. 10.1371/journal.pone.0039465PubMed CentralView ArticlePubMedGoogle Scholar
- Lee H, Suk J, Patrick C, Bae E, Chio J, Rho S, Hwang D, Masliah E, Lee S: Direct transfer of alpha-synucelin from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010, 285: 9262-9272. 10.1074/jbc.M109.081125PubMed CentralView ArticlePubMedGoogle Scholar
- Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ: Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008, 40(9):1835-1849. 10.1016/j.biocel.2008.01.017View ArticlePubMedGoogle Scholar
- Hoepken HH, Gispert S, Azizov M, Klinkenberg M, Ricciardi F, Kurz A, Morales-Gordo B, Bonin M, Riess O, Gasser T, Kogel D, Steinmetz H, Auburger G: Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 2008, 212(2):307-313. 10.1016/j.expneurol.2008.04.004View ArticlePubMedGoogle Scholar
- Schapira A, Cooper J, Dexter D, Jenner P, Marsden C: Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989, 1: 1269.View ArticlePubMedGoogle Scholar
- Lin M, Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443: 787-795. 10.1038/nature05292View ArticlePubMedGoogle Scholar
- Sas K, Robotka H, Toldi J, Vecsei L: Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007, 257(1–2):221-239.View ArticlePubMedGoogle Scholar
- Li RH, Liu YQ, Li ZB, Yang L, Wang SW, Guan MX: Failures in mitochondrial tRNA(Met) and tRNA(Gln) metabolism caused by the novel 4401A > G mutation are involved in essential hypertension in a Han chinese family. Hypertension 2009, 54(2):329-337. 10.1161/HYPERTENSIONAHA.109.129270PubMed CentralView ArticlePubMedGoogle Scholar
- Kim HY, Lee KY, Lu Y, Wang JG, Cui L, Kim SJ, Chung JM, Chung K: Mitochondrial Ca2+ uptake is essential for synaptic plasticity in pain. J Neurosci 2011, 31(36):12982-12991. 10.1523/JNEUROSCI.3093-11.2011PubMed CentralView ArticlePubMedGoogle Scholar
- Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, Edwards RH: Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 2011, 286(23):20710-20726. 10.1074/jbc.M110.213538PubMed CentralView ArticlePubMedGoogle Scholar
- Lizard G, Rouaud O, Demarquoy J, Cherkaoui-Malki M, Iuliano L: Potential roles of peroxisomes in Alzheimer’s disease and in dementia of the Alzheimer’s type. J Alzheimers Dis 2012, 29(2):241-254.PubMedGoogle Scholar
- Davidson WS, Jonas A, Clayton DF, George JM: Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998, 273(16):9443-9449. 10.1074/jbc.273.16.9443View ArticlePubMedGoogle Scholar
- Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van derPutten H, Probst A, Kremmer E, Kretzschmar HA, Haass C: Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000, 20(17):6365-6373.PubMedGoogle Scholar
- Dixon C, Mathias N, Zweig RM, Davis DA, Gross DS: Alpha-Synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 2005, 170(1):47-59. 10.1534/genetics.104.035493PubMed CentralView ArticlePubMedGoogle Scholar
- Budd SL, Nicholls DG: Mitochondria, calcium regulation, and acute glutramate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996, 67: 2282-2291.View ArticlePubMedGoogle Scholar
- Esteves A, Arduino D, Silva D, Oliveira C, Cardoso S: Mitochondrial dysfunction: the road to alpha-synuclein oligomerisation in PD. Parkinsons Dis 2010, 2011: 1-20.View ArticleGoogle Scholar
- Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006, 38(5):515-517. 10.1038/ng1769View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.